共 11 条
[1]
Rationale and design of the anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-throm bolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized,double-blind,placebo-co. Gibson CM,Mega JL,Burton P,et al. American Heart Journal . 2011
[2]
The efficacy and safety of apixaban,an oral,direct factor Xa inhibitor,as thromboprophylaxis in patients following total knee replacement. Lassen MR,Davidson BL,Gallus A,et al. Journal of Thrombosis and Haemostasis . 2007
[3]
New options in anticoagulation for atrial fibrillation. Gregory J Del Zoppo,Misha Eliasziw. The New England Journal of Medicine . 2011
[4]
ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. CB Granger,JH Alexander,JJ McMurray,RD Lopes,EM Hylek,M Hanna,HR Al-Khalidi,J Ansell,D Atar,A Avezum,MC Bahit,R Diaz,JD Easton,JA Ezekowitz,G Flaker,D Garcia,M Geraldes,BJ Gersh,S Golitsyn,S Goto,AG Hermosillo,SH Hohnloser,J Horowitz,P Mohan,P Jansky,BS L. The New England Journal of Medicine . 2011
[5]
Apixaban in patients with atrial fibrillation. S.J. Connolly,J. Eikelboom,C. Joyner. The New England Journal of Medicine . 2011
[6]
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. M.R. Patel,K.W. Mahaffey,J. Garg. The New England Journal of Medicine . 2011
[7]
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. SZ Goldhaber,A Leizorovicz,AK Kakkar. The New England Journal of Medicine . 2011
[8]
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. M.R. Lassen,A. Gallus,G.E. Raskob,G. Pineo,D. Chen,L.M. Ramirez. The New England Journal of Medicine . 2010
[9]
Apixaban with antiplatelet therapy after acute coronary syndrome. JH Alexander,RD Lopes,S James. The New England Journal of Medicine . 2011
[10]
Dabigatran versus warfarin in patients with atrial fibrillation. S.J. Connolly,M.D. Ezekowitz,S. Yusuf. The New England Journal of Medicine . 2009